Context Therapeutics Inc. Common Stock (CNTX)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for durable earnings power and a margin of safety. Context Therapeutics is a clinical-stage biotech with no reported revenue in any period shown. Its lead candidate, CTIM-76, is a Claudin 6 x CD3 bispecific antibody, and it depends on a collaboration with Integral Molecular. That is a pipeline option, not a moat. The financials confirm weakness: in fiscal 2025, the year ended 2025-12-31, it lost $36.1 million, or $0.38 per diluted share; in fiscal 2024, it lost $26.7 million, or $0.46; and in fiscal 2023, it lost $24.0 million, or $1.50. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $14.6 million, or $0.15 per diluted share, worse than the $8.7 million loss in fiscal Q1 2026, the quarter ended 2026-03-31. Trailing free cash flow was negative $40.5 million, which FairStock calculates as a -160.4% FCF yield against the $25.3 million market cap. At the 2026-10-13 close of $0.28, FairStock's P/B is 0.67 and P/E is -0.57. FairStock also shows ROE of -76.14%, ROCE of -45.70%, Piotroski F-Score of 1/9, Altman Z-Score of -1.79, and a FairStock Score of 26/100. Debt is low at D/E 0.01, but low debt does not offset negative earnings. The Lynch category is none because it has lost money each of the last four years. I see no earnings-based valuation and no competitive moat. Until CTIM-76 shows credible clinical value and the company can fund itself without destroying equity, the stock is speculative, not a Graham-style bargain.

In plain English: Context Therapeutics is a small drug developer working on a treatment for solid tumors. It has no product sales and keeps losing money, so the business looks weak and unproven. At 28 cents a share, the price looks low compared with its accounting value, but the company is burning cash, so cheapness is not the same as safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer